Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00887536 · ClinicalTrials.gov registry record · Phase 3
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase 3 study, sponsored by NSABP Foundation.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,613
- Enrollment target
NCT00887536: Completed Phase 3 study, sponsored by NSABP Foundation.
NCT00887536 is a Phase 3 study that has completed, run by NSABP Foundation. The registered enrollment target is 1,613 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (109% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00887536, a Phase 3 study, has completed, sponsored by NSABP Foundation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,613 participants
- Enrollment target
Study Summary
The main purpose of this study is to learn if adding bevacizumab to standard treatment with chemotherapy (docetaxel, doxorubicin, and cyclophosphamide) for early stage HER2-negative breast cancer will prevent breast cancer from returning. A second purpose of this study is to learn if adding bevacizumab to treatment with chemotherapy will help women with HER2-negative breast cancer live longer. The researchers also want to learn about the side effects of the combination of drugs used in this study.
Interventions
- DRUG cyclophosphamide
- DRUG bevacizumab
- DRUG docetaxel
- DRUG pegfilgrastim
- DRUG doxorubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,613 participants |
| Start Date | 2009-05 |
| Est. Completion | 2018-02 |
| Phase | Phase 3 |
What the finished NCT00887536 record still lists
NCT00887536 is an interventional study that assigns participants to a tested intervention. Its 1,613 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (109% higher).
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00887536 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00887536 about?
NCT00887536 is a clinical study titled "A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer". The main purpose of this study is to learn if adding bevacizumab to standard treatment with chemotherapy (docetaxel, doxorubicin, and cyclophosphamide) for early stage HER2-negative breast cancer will prevent breast cancer from returning. A second purpose of this study is to learn if adding bevacizu...
What is the current status of trial NCT00887536?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,613 participants. The study started on 2009-05. Estimated completion is 2018-02.
What interventions are being tested in trial NCT00887536?
The interventions under investigation include: cyclophosphamide (DRUG), bevacizumab (DRUG), docetaxel (DRUG), pegfilgrastim (DRUG), doxorubicin (DRUG).
Who is sponsoring clinical trial NCT00887536?
This trial is sponsored by NSABP Foundation, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00887536's enrollment target sits among peer trials
1,613 142nd of 2000 higher than 1,859 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06959524 · 1,616 participants · NA
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
- NCT06271590 · 1,605 participants · NA
MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels
- NCT00646022 · 1,600 participants
Natural History of Familial Carcinoid Tumor
- NCT03109197 · 1,600 participants
Sudden Unexplained Death in Childhood (SUDC) Registry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia